Publication
Title
Clinical trial: a randomized trial of pegylated-interferon--2a plus ribavirin with or without amantadine in treatment-naive or relapsing chronic hepatitis C patients
Author
Abstract
P>Background The combination therapy of pegylated-interferon-alpha 2a plus ribavirin is considered as the standard of care for patients with chronic hepatitis C. A sustained viral response is obtained in 40-50% of naive patients with genotype 1 and in around 80% of naive patients with genotype 2 or 3. Aim To assess whether amantadine, added to the conventional combination therapy, could improve the treatment efficacy. Methods In all, 630 patients (intent-to-treat population) with chronic hepatitis C were randomized into two groups: 316 patients (treatment group) received pegylated-interferon-alpha 2a (180 mu g once weekly) plus ribavirin (1000-1200 mg/daily) with amantadine (200 mg/daily); 314 patients (control group) received pegylated-interferon-alpha 2a (180 mu g once weekly) plus ribavirin (1000-1200 mg/daily) without amantadine. The duration of the treatment was 48 weeks for genotypes 1, 4, 5 and 6, and 24 weeks for genotypes 2 and 3. Results There was no statistically significant difference between treatments groups for any of the variables tested for. Subgroups of patients likely to take advantage of the addition of amantadine were not identified. Conclusions This large study definitely excludes the role of amantadine in addition of conventional combination therapy in the treatment of chronic hepatitis C patients.
Language
English
Source (journal)
Alimentary pharmacology and therapeutics. - Oxford
Publication
Oxford : 2009
ISSN
0269-2813
Volume/pages
30:4(2009), p. 352-363
ISI
000268166300004
Full text (Publisher's DOI)
Full text (open access)
UAntwerpen
Faculty/Department
Research group
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 24.02.2012
Last edited 06.08.2017
To cite this reference